Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab-Reference-Cited by-同舟云学术

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

Published:2019-11-02 Issue:18 Volume:8 Page:7637-7643
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Moser Justin C.¹^ORCID,Chen Danli²,Hu‐Lieskovan Siwen³,Grossmann Kenneth F.³,Patel Shiven³,Colonna Sarah V.³,Ying Jian²,Hyngstrom John R.⁴

Affiliation:

1. HonorHealth Research Institute Scottsdale AZ USA

2. Division of Public Health, Study Design and Biostatistics Center Department of Family Medicine Huntsman Cancer Institute University of Utah Salt Lake City UT USA

3. Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City UT USA

4. Surgical Oncology Department of Surgery Huntsman Cancer Institute University of Utah Salt Lake City UT USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2625

Reference19 articles.

1. BRAF and RAS mutations in human lung cancer and melanoma;Brose MS;Cancer Res,2002

2. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

3. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma